Identification of a novel mutation in the PHKA2 gene in a child with liver cirrhosis
Author:
Beyzaei Zahra1, Ezgu Fatih2, Imanieh Mohammad Hadi3, Geramizadeh Bita14
Affiliation:
1. Shiraz Transplant Research Center (STRC) , Shiraz University of Medical Sciences , Shiraz , Iran 2. Department of Pediatric Metabolism and Genetics , Gazi University Faculty of Medicine , Ankara , Turkey 3. Gastroenterology and Hepatology Research Center , Shiraz University of Medical Sciences , Shiraz , Iran 4. Department of Pathology , Shiraz University of Medical Sciences , Shiraz , Iran
Abstract
Abstract
Objectives
Glycogen storage diseases (GSDs) are heterogeneous disorders caused by various enzyme deficiencies. GSD type IX α2, the most common subtype of GSD IX, is due to a deficiency of hepatic phosphorylase kinase. Herein we will report a novel mutation in this disease with an unusual presentation.
Case presentation
we describe a 3-year-old boy who suffered from hepatomegaly, fatty liver disease, and liver cirrhosis. The cause of cirrhosis at a young age was unknown based on the laboratory data and liver biopsy, so we performed a targeted-gene sequencing (TGS) covering 450 genes involved in inborn metabolic diseases consisting of glycogen storage disorders genes with hepatic involvement. He was found out to have a rare novel pathogenic variant in the PHKA2 gene.
Conclusions
This novel variant c.2226+2T > C expands the mutational spectrum of the PHKA2 gene. Also, severe liver damage (cirrhosis) in patients with GSD- IX α2 has rarely been reported, which needs further discussion. We hypothesize that unidentified PHKA2 variants may be a rare cause of childhood liver cirrhosis.
Publisher
Walter de Gruyter GmbH
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Pediatrics, Perinatology and Child Health
Reference10 articles.
1. Tsilianidis, LA, Fiske, LM, Siegel, S, Lumpkin, C, Hoyt, K, Wasserstein, M, et al.. Aggressive therapy improves cirrhosis in glycogen storage disease type IX. Mol Genet Metabol 2013;109:179–82. https://doi.org/10.1016/j.ymgme.2013.03.009. 2. Bali, DS, Goldstein, JL, Fredrickson, K, Austin, S, Pendyal, S, Rehder, C, et al.. Clinical and molecular variability in patients with PHKA2 variants and liver phosphorylase b kinase deficiency. J Inherit Metab Dis 2017;37:63–72. https://doi.org/10.1007/8904_2017_8. 3. Herbert, M, Goldstein, JL, Rehder, C, Austin, S, Kishnani, PS, Bali, DS. Phosphorylase kinase deficiency. In: Adam, MP, Ardinger, HH, Pagon, RA, Wallace, SE, Bean, LJH, Mirzaa, G, et al., editors. GeneReviews. Seattle, WA: University of Washington; 2011:1993–2021 pp. 4. Nguyena, NL, Ngocc, CTB, Vuc, CD, Tunga, NV, Nguyen, HH. A novel frameshift PHKA2 mutation in a family with glycogen storage disease type IXa: a first report in Vietnam and review of literature. Clin Chim Acta 2020;508:9–15. https://doi.org/10.1016/j.cca.2020.05.010. 5. Richards, S, Aziz, N, Bale, S, Bick, D. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med 2015;17:405–23. https://doi.org/10.1038/gim.2015.30.
|
|